Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Medtronic
Citi
QuintilesIMS
Accenture
Argus Health
Moodys
Fuji

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NIPENT

« Back to Dashboard

Clinical Trials for Nipent

Trial ID Title Status Sponsor Phase Summary
NCT00038025 A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Completed M.D. Anderson Cancer Center Phase 2 The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
NCT00131313 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status Astex Pharmaceuticals Phase 4 This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
NCT00131313 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status Mena, Raul, M.D. Phase 4 This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
NCT00131313 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status Pharmatech Oncology Phase 4 This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nipent

Condition Name

Condition Name for Nipent
Intervention Trials
Lymphoma 2
Chronic Lymphocytic Leukemia 2
Sickle Cell Disease 2
Follicular Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nipent
Intervention Trials
Lymphoma 3
Leukemia, Lymphoid 3
Leukemia, Lymphocytic, Chronic, B-Cell 3
Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nipent

Trials by Country

Trials by Country for Nipent
Location Trials
United States 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nipent
Location Trials
Texas 4
Maryland 3
Indiana 2
Florida 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nipent

Clinical Trial Phase

Clinical Trial Phase for Nipent
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nipent
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nipent

Sponsor Name

Sponsor Name for Nipent
Sponsor Trials
Astex Pharmaceuticals 3
M.D. Anderson Cancer Center 2
Mena, Raul, M.D. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nipent
Sponsor Trials
Industry 7
Other 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Fuji
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Daiichi Sankyo
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.